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Introduction
Interprofessional education (IPE) is 
a cornerstone in advancing health 
professional education, with the aim 
of improving the overall quality of 
healthcare.1 The World Health Organization 
(WHO) states: “Interprofessional education 
occurs when two or more professions 
learn about, from and with each other 
to enable effective collaboration and improve health outcomes”.2 IPE 
enables students to function within the broader health workforce 
team, with the aim of transferring this skill into their future practice 
environment, by having a shared goal to improve the quality of care 
and patient outcomes.  
Teamwork and interprofessional collaboration are critical to patient 
safety; however, many allied health graduates often feel ill-prepared 
to participate in a collaborative practice setting. There are many 
barriers to the systematic integration of interprofessional education 
and collaboration in pharmacy undergraduate training programmes in 
South Africa. Not many South African pharmacy schools are linked to a 
medical school or have regular access to teaching hospitals.  
In the School of Pharmacy at the University of the Western Cape, 
members of staff in Clinical Pharmacy are required to precept 
pharmacy students during their clinical placements across Cape Town 
health facilities. Following a patient-centred approach directed at 
medicine-related needs, academic pharmacists work with patients, 
their physicians and families towards a safe and effective medication 
therapy plan, which is modelled on the principles of teamwork and 
collaboration with students from other health disciplines. 
With a case vignette, I highlight the role of faculty in the practice 
environment working within a team in the provision of quality care.
Case Scenario
The following patient was presented to the healthcare team consisting 
of nurses, doctors and pharmacists during their routine early morning 
rounds at a health care facility.
Patient presentation
Nosipho* is a 34 year-old female who presented to the district hospital 
with complaints of severe headache and dizziness over the previous 
few weeks. Her past medical history revealed that she was known to 
be living with the human immunodeficiency virus (HIV), with a CD T 
helper cell lymphocyte (CD4) count of 240 cells per microlitre, but not 
on antiretroviral treatment. She reported no other chronic medical 
conditions and also denied using alcohol, tobacco or recreational 
drugs. Upon investigation she was found to be severely anaemic with a 
haemoglobin of 4.4 g/L and was given one unit of red blood cells. Oral 
corticosteroid therapy with prednisone was initiated for the treatment 
of possible haemolysis. She was transferred to a tertiary institution for 
further management.
During admission to the tertiary institution, blood investigations as 
well as her clinical presentation confirmed the diagnosis of haemolytic 
anaemia. She had a low haemoglobin (4.9 g/L), as well as a low red 
blood cell count (2.74 x1012/L). Her lactic acid dehydrogenase (LDH) 
level was increased (901 u/L) and the COOMBS test was positive, 
confirming the diagnosis of haemolytic anaemia. Iron levels were 
normal (14.7 umol/L).
Close inspection of her skin and soft palate during the ward round 
raised the suspicion of potential Kaposi Sarcoma (KS). She presented 
with several purple coloured lesions on the skin as well as a non-itchy 
patch on the soft palate of the mouth.
Kaposi Sarcoma (KS)
Kaposi Sarcoma is a vascular tumour, which arises in multifocal sites. 
The skin is most commonly involved, though virtually any organ can 
be involved. The skin lesions of KS most often develop on the legs or 
face, but they can also appear in other areas. Lesions on the legs or in 
the groin area can sometimes block the flow of fluid out of the legs. 
This can lead to painful swelling in the legs and feet. KS lesions can also 
develop on mucous membranes (the linings of certain parts inside the 
body) such as inside the mouth and throat and on the outside of the 
eye and inner part of the eyelids. The lesions are usually not painful or 
itchy.3, 4
Kaposi Sarcoma is caused by infection with the human Herpes virus 8 
and disease progression involves a process of viral oncogenesis within 
a context of deregulated cytokines and immunosuppression. It is the 
most common malignancy in HIV-infected patients in Africa and has 
an incidence of 5 per 100 000 individuals being at risk of developing it.5
The most important treatment for KS targets any immune deficiency 
that exists as well as any related infections. It has been noted that 
antiretroviral therapy alone improves the outcome of HIV-associated 
KS. In South Africa, addition of chemotherapy to antiretroviral therapy 
(ART) has been shown to achieve higher KS response over 12 months 
as compared to ART alone. The most common chemotherapy includes 
paclitaxel or doxorubicin, bleomycin and vinblastine or vincristine. 
Surgical removal is also an option; however, more lesions often appear 
at the site of incision.6, 7
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Haemolytic anaemia
Haemolytic anaemia is a disorder where red blood cells are destroyed 
at a rate faster than that by which they can be produced in the bone 
marrow. The normal life span of red blood cells is 120 days. Autoimmune 
haemolytic anaemia is the most common extracorpuscular haemolytic 
anaemia and it is due to autoantibodies directed against components 
of the erythrocyte membrane. Haemolysis can manifest as jaundice 
and patients often present with fatigue, dark urine and severe back 
pain. Possible causes of autoimmune haemolytic anaemia include 
medicines, lupus and HIV.8
Ideally, haemolytic anaemia should be managed in conjunction with 
a haematologist. Corticosteroids and treatment of any underlying 
disorder are the mainstay of therapy for patients with autoimmune 
haemolytic anaemia. Transfusion therapy is challenging and the most 
compatible red blood cells should be given. Refractory cases may 
require splenectomy, intravenous gamma globulin, plasmapheresis or 
cytotoxic agents.9
Clinical Dilemma
Reviewing Nosipho’s case, the following treatments were required for 
the management of KS and haemolytic anaemia:
1. Initiation of first line ARVs, namely, tenofovir, emtricitabine and 
efavirenz.  The necessary baseline investigations were performed.
2. Nosipho’s most recent CD4 count was above 200 cells per microlitre, 
however due to the current KS she was regarded as World Health 
Organization clinical stage 4, and required daily cotrimoxazole to 
prevent acquiring opportunistic infections.
3. She was also referred to the oncology unit to start chemotherapy 
for the KS.
4. For the treatment of haemolytic anaemia, glucocorticosteroids 
(prednisone 60mg daily) were initiated. 
The interprofessional health care team discussed the management of 
Nosipo’s condition. As an academic pharmacist, practising in a real-life 
environment, I engaged with the medical team and discussed some 
concerns with the proposed treatment.
Firstly, we discussed the use of steroids in patients with KS as they pose 
a risk for increased KS-associated immune reconstitution inflammatory 
syndrome (IRIS) and mortality. In a case-control study, researchers 
reported that glucocorticosteroid use was identified as a risk factor for 
mortality with an adjusted odds ratio of 4.7.10 Therefore, the benefits 
and the risks had to be determined.
Secondly, Nosipho had a CD4 of above 200 cells per microlitre; 
however due to coinfections she was classified as WHO clinical 
stage 4 and would benefit from cotrimoxazole prophylaxis. On the 
other hand, co-trimoxazole has been implicated in cases of bone 
marrow suppression resulting in fatalities. In patients with Glucose-6-
phosphate dehydrogenase (G6PD) deficiency, reports of haemolysis 
from cotrimoxazole therapy has been reported.
Patient Outcome
Nosipho’s condition improved. Her haemoglobin improved to 
9.4 g/L, after receiving an additional 3 units of red blood cells. She 
received counselling and education on the management of HIV and 
was initiated on ARVs (first-line therapy). Initiation of cotrimoxazole, 
for the prevention of opportunistic infections, was recommended at 
the next follow-up visit. In a subsequent visit to the oncology unit, 
chemotherapy was initiated.
Undergraduate pharmacy and medical students participated in a 
stimulating discussion, directed not only at the medical conditions 
presented to them, but to learn about how medicine use decisions are 
made in patients with complex disease conditions. 
Conclusions 
The case vignette provided insight into the potential benefits of 
introducing interprofessional education into the undergraduate 
pharmacy training programme. An interprofessional team, along 
with students, created a meaningful learning environment in the 
management of a complex disease. Since this was not a “text book” 
patient, but a real-world patient case, students were required to 
engage in critical thinking, which led to a positive health outcome.
Key messages
1. A pharmacist is needed wherever medicine is used. As members 
of the interprofessional team pharmacists have a defined role in 
optimising medicine therapy management.
2. Higher education institutions should work towards incorporating 
interprofessional education, which extends beyond the classroom 
to include training in a clinical practice setting. Such an approach 
would strengthen pharmacy students’ communication and 
teamwork skills.
3. Research into ‘best practice’ for implementation of interprofessional 
education in pharmacy schools is required.
* Not the patient’s real name
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